

**A. CLASSIFICATION OF SUBJECT MATTER.**Int. Cl.<sup>7</sup> C07F 15/00; A61K 31/555, 33/24; A61P 35/00.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

See electronic database consulted below.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database, and where practicable, search terms used)

STN Substructure Search

STN (Medline, CA, WPIDS): Keywords- isoflav?, genistein, daidzein, flavan?, flavon?, platin?, cisplat?

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to Claim No. |
|-----------|--|-----------------------|
| X         | STN File Medline, abstract accession number 2002151803<br>& S. Giacomelli et al., Life Sciences (8 February 2002), 70(12), pages 1447-1459, 'Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo in the activity of cisplatin'. |                       |
| X         | STN File Medline, abstract accession number 2000404390<br>& S. Caltagirone et al., International Journal of Cancer (15 August 2000), 87(4), pages 595-600, 'Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential'.                         |                       |

☒ Further documents are listed in the continuation of Box C.

|  |   |     |  |
|--|---|-----|--|
| * Special categories of cited documents: |   |     |  |
| "A"                                      | document defining the general state of the art which is not considered to be of particular relevance  | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "E"                                      | earlier application or patent but published on or after the international filing date   | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "L"                                      | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O"                                      | document referring to an oral disclosure, use, exhibition or other means  | "&" | document member of the same patent family  |
| "P"                                      | document published prior to the international filing date but later than the priority date claimed  |     |  |

|  |   |
|--|---|
| Date of the actual completion of the international-type search<br>16 December 2002   | Date of mailing of the international-type search report                         |
| Name and mailing address<br>AUSTRALIAN PATENT OFFICE<br>PO BOX 200, WODEN ACT 2606, AUSTRALIA<br>E-mail address: pct@ipaaustralia.gov.au<br>Facsimile No. (02) 6285 3929 | Authorized Officer<br><br><b>MARIE-ANNE FAM</b><br>Telephone No. (02) 6283 2254 |

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|---|---|-----------------------|
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to Claim No. |
| X   | STN File Medline, abstract accession number 96273517<br>& G. Scambia et al., European Journal of Cancer (May 1996), 32A(5), pages 877-882, 'Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin'.  |                       |
| X   | STN File Medline, abstract accession number 91191699<br>& W. R. Waud et al., Cancer Chemotherapy and Pharmacology (1991), 27(6), pages 456-463, 'Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia'.  |                       |
| X   | STN File Medline, abstract accession number 91107211<br>& S. S. Neelam et al., Investigational New Drugs (August 1990), 8(3), pages 263-268, 'Combination of flavone acetic acid (FAA) with adriamycin, cisplatin and difluoromethylornithine (DFMO) in vitro against human colon cancer cells'.        |                       |
| X   | STN File Medline, abstract accession number 92032982<br>& G. Scambia et al., Anti-Cancer Drugs (October 1990), 1(1), pages 45-48, 'Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth'.  |                       |
| X   | STN File CA, abstract number 119:131038<br>& R. De Vincenzo et al, Acta Medica Romana (1992), 30(1-2), pages 126-132, 'Flavonoids and negative control of cell proliferation in ovarian tumors'.  |                       |
| X   | Acta Poloniae Pharmaceutica Drug Research, 1999, 56(2), pages 159-167, E. Zyner and J. Ochocki, 'Platinum (II) and palladium (II) N, O-chelates with substituted flavanone containing ligands'.<br>(see the whole document, in particular page 162, scheme 1 and page 164, table 1)                     |                       |
| X   | Pharmazie, 1999, 54(12), pages 945-946, E. Zyner et al., 'Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation'.<br>(see the whole document)  |                       |
| X   | Anticancer Research, 1999, volume 19, pages 221-228, W. Lei et al., 'Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells'.<br>(see the whole document, in particular the abstract and page 224) |                       |
| X   | Pediatric Neurosurgery, 2000, volume 33, pages 123-131, S. Khoshyomn et al., 'Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells'.<br>(see the whole document)  |                       |

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|---|---|-----------------------|
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to Claim No. |
| X   | Natural Product Sciences, 2000, 6(4), pages 165-169, B-J. Kang et al., 'Scientific analysis of formulation theory of Chungpesagan-tang; in vitro cytotoxicity of cisplatin combined with Chungpesagan-tang'.<br>(see the whole document, in particular the abstract and page 168) |                       |